DOCSLIB.ORG

Efficacy and Tolerability of the Dual 5A-Reductase Inhibitor, Dutasteride, in the Treatment of Benign Prostatic Hyperplasia in African-American Men

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Efficacy and Tolerability of the Dual 5A-Reductase Inhibitor, Dutasteride, in the Treatment of Benign Prostatic Hyperplasia in African-American Men Prostate Cancer and Prostatic Diseases (2006) 9, 432–438 & 2006 Nature Publishing Group All rights reserved 1365-7852/06 $30.00 www.nature.com/pcan ORIGINAL ARTICLE Efficacy and tolerability of the dual 5a-reductase inhibitor, dutasteride, in the treatment of benign prostatic hyperplasia in African-American men CG Roehrborn1 and P Ray2 1Department of Urology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA and 2Division of Urology, Cook County Hospital, Chicago, IL, USA The efficacy and tolerability of dutasteride (0.5 mg daily for 2 years) in African-Americans (n ¼ 161), compared with Caucasians (n ¼ 3961), was assessed in a post hoc analysis of data from three Phase III clinical trials. Dutasteride significantly reduced serum dihydrotestosterone levels by 490% and significantly improved subjective (symptom score) and objective (prostate volume, peak urinary flow rate, risk of benign prostatic hyperplasia-related surgery and acute urinary retention) outcomes in both African-Americans and Caucasians. For all efficacy measures, there was no statistically significant treatment-by-race interaction and dutasteride was well tolerated in both racial groups. Therefore, dutasteride demonstrated similar efficacy and safety profiles in African- Americans and Caucasians. Prostate Cancer and Prostatic Diseases (2006) 9, 432–438. doi:10.1038/sj.pcan.4500911; published online 19 September 2006 Keywords: benign prostatic hyperplasia; African-American men; dutasteride Introduction prostate-specific antigen (PSA) levels.18,19 Cultural fac- tors – such as the tendency to report symptoms – and Benign prostatic hyperplasia (BPH) is one of the most behavioural factors – for example, diet – may also 1 common diseases of ageing men, affecting more than contribute to racial differences in the incidence and 50% of men in their sixties and 90% of men over the age progression of BPH. 2 of 70 years. In clinical studies, African-American men In addition to the incidence and progression of BPH, have been shown to have a similar, or greater, risk of these genetic/biological, cultural and behavioural factors 3–7 BPH compared with Caucasian men. In an analysis of may result in racial differences in response to BPH community-based studies, the severity of lower urinary pharmacotherapy. No studies to date have compared the tract symptoms (LUTS) was significantly greater among response to BPH pharmacotherapy in different racial African-Americans compared with Caucasians, although groups, in part owing to the low numbers of minorities African-American men reported less bother for each unit in clinical trials.20,21 The lack of data on the efficacy and 8 increase in LUTS severity. In addition, a recent retro- tolerability of BPH pharmacotherapy in African-Ameri- spective cohort study showed that African-American can men may hinder efforts to optimize management of men have a significantly higher risk of BPH progression the disease in this patient population. 9 than Caucasian-American men. Dutasteride is unique among BPH pharmacotherapies, Racial differences in BPH incidence and progression inhibiting both of the 5a-reductase isoenzymes (type 1 may be due, in part, to genetic/biological factors. Indeed, and type 2) that convert testosterone to DHT, the primary there have been reports of racial differences in circulating androgen responsible for prostate growth.22 Inhibition of testosterone levels and the ratio of dihydrotestosterone both type 1 and type 2 5a-reductase isoenzymes with 10,11 (DHT) to testosterone; variations in the gene encod- dutasteride results in near-maximal (490%) suppression 12,13 ing 5a-reductase type 2; androgen receptor expres- of DHT, which is evident within 2 weeks and sustained 14 sion; levels of insulin growth factor binding protein-3 at 24 and 48 months.23,24 Results of Phase III clinical trials 11,15 and sex hormone binding globulins; prostate volume show that dutasteride improves BPH symptoms, reduces 16,17 and prostate transition zone volume; and serum the incidence of acute urinary retention, decreases the risk of BPH-related surgery and is well tolerated.23,24 The Correspondence: Dr CG Roehrborn, Department of Urology, current post hoc analysis of data from three identically The University of Texas Southwestern Medical Center at Dallas, designed, well-controlled clinical trials involving over 5323 Harry Hines Blvd., J8-130, Dallas, TX 75390-9110, USA. 24,25 E-mail: [email protected] 4000 BPH patients was performed to assess the Received 8 June 2006; accepted 20 July 2006; published online 19 efficacy and tolerability of dutasteride in a sub-popula- September 2006 tion of 161 African-Americans (82 and 79 in dutasteride Dutasteride in African-American men with BPH CG Roehrborn and P Ray and placebo groups, respectively), compared with treatment, race and a treatment-by-race interaction. For 433 Caucasians, over 2 years of treatment. all other efficacy measures and pharmacodynamic measures, treatment-by-race interactions were assessed with t-tests from general linear models that included effects for treatment, race, cluster and baseline as well as Methods a treatment-by-race interaction. Treatment comparisons A post hoc analysis of data from three Phase III, within each of the race subgroups were performed using randomized, double-blind, placebo-controlled trials, the statistical models listed above without the race and during which patients received either dutasteride treatment-by-race interaction terms. Statistics were per- (0.5 mg/day) or placebo, was performed. Men aged 50 formed on both last-observation-carried-forward (LOCF) years or above with moderate-to-severe symptoms of and observed values from each clinic visit. The two BPH (American Urological Association Symptom Index methods yielded similar results; therefore, only LOCF (AUA-SI) score X12),26 an enlarged prostate (X30 cc) results are reported. and a PSA X1.5 ng/ml were evaluated. The methodo- logy and primary outcomes of the studies have been reported previously.24 Results Patients Efficacy and safety analysis Of the 4325 patients randomized to treatment in the three Serum DHT and testosterone levels were measured at studies, 161 were African-American (3.7%), 3961 were baseline and at months 12 and 24, whereas mean PSA Caucasian (91.6%) and 203 were Asian, American levels were assessed at baseline and month 24. Hispanic or of other ethnic origin (4.7%). The term Both objective and subjective efficacy measures were African-American is used to describe the 161 black men, evaluated for the intention-to-treat (ITT) population. of whom only eight were recruited at study sites outside Objective measures included the incidence of acute the USA. Demographics and baseline clinical character- urinary retention (defined as inability to urinate and istics were similar in African-American and Caucasian requirement for bladder catheterization) and the inci- patients, and in the dutasteride and placebo treatment dence of BPH-related surgical intervention over the groups (Table 1). 2-year treatment period. Additional objective measures, assessed at month 24, were the mean percentage change DHT and testosterone concentrations from baseline in total prostate volume and in prostate There were no significant differences in mean baseline transition zone volume (measured by transrectal ultra- serum DHT levels between the dutasteride and placebo sound) and mean change in peak urinary flow rate groups, or between African-Americans (421.9 pg/ml in (Qmax) (measured with a Dantec Uroflow Meter). The the dutasteride group; 389.3 pg/ml in the placebo group) subjective efficacy measure was the mean change from and Caucasians (428.1 pg/ml and 416.7 pg/ml in the baseline in AUA-SI score at month 24. For the AUA- dutasteride and placebo groups, respectively). Mean SI, the total score ranges from 0 to 35 with higher baseline serum testosterone levels were slightly lower scores reflecting a greater impairment. Scores of X8 and among African-American patients compared with Cau- X20 correspond to moderate and severe symptoms, casians in both dutasteride (3718.3 versus 4036.8 pg/ml) respectively.26 and placebo groups (3757.0 versus 4001.0 pg/ml). The incidence of drug-related adverse events is Dutasteride significantly (Po0.001) reduced DHT presented for 6-month time periods throughout the levels from baseline compared with placebo in both treatment. racial groups. At month 24, the adjusted mean changes in DHT levels from baseline in dutasteride and placebo groups, respectively, were À91.8 and þ 9.3% among Statistics African-Americans and À92.6 and þ 0.2% among For acute urinary retention and BPH-related surgical Caucasians. Dutasteride also significantly (Po0.001) intervention, treatment-by-race interaction was assessed increased testosterone levels from baseline compared using a Cox proportional hazards model, with effects for with placebo in both African-Americans (adjusted mean Table 1 Demographics and baseline clinical characteristics of African-American and Caucasian patients in the dutasteride and placebo treatment groups African-Americans Caucasians Dutasteride (n ¼ 82) Placebo (n ¼ 79) Dutasteride (n ¼ 1975) Placebo (n ¼ 1986) Age (years) 64.8 (50–82) 63.7 (47–81) 66.6 (50–91) 66.3 (50–91) Prostate volume (cm3) 54.9 (30.7–161.8) 57.0 (30.6–180.3) 55.0 (19.2–274.2) 54.0 (16.6–177.1) Transition zone volume (cm3) 29.2 (6.2–118.7) 32.0 (7.9–162.5) 26.8 (1.4–146.9) 26.6 (0.8–126.4) Qmax (ml/s) 10.4 (4.9–22.9) 9.4 (3.0–16.5) 10.1 (2.2–33.0) 10.4 (2.5–31.8) Serum PSA (ng/ml) 4.5 (1.5–9.8) 4.3 (1.3–8.8) 4.0 (0.7–13.0) 4.0 (1.1–16.9) AUA-SI score 16.7 (2–33) 17.3 (2–31) 17.1 (1–35) 17.1 (2–35) Abbreviations: AUA-SI, American Urological Association Symptom Index; PSA, prostate-specific antigen; Qmax, peak urinary flow rate.
Load more

Recommended publications
  • Nonsurgical Hair Restoration Treatment
    COSMETIC DERMATOLOGY Nonsurgical Hair Restoration Treatment Roya S. Nazarian, BA; Aaron S. Farberg, MD; Peter W. Hashim, MD, MHS; Gary Goldenberg, MD androgenic alopecia (AGA).3 Currently, minoxidil and PRACTICE POINTS finasteride are the only US Food and Drug Administration • Hair loss is a common phenomenon in both men (FDA)–approved medications for the treatment of hair and women and can seriously impact psychosocial loss; however, other nonsurgical treatment options have functioning. gained popularity, including dutasteride, spironolactone, • There are numerous US Food and Drug Administration– low-level laser therapy (LLLT), platelet-rich plasma (PRP), approved and off-label nonsurgical treatment options microneedling, stemcopy cells, and nutraceutical supplements. for alopecia. Dermatologists should be well versed in We provide an overview of these treatment options to these treatment modalities and the associated side- help dermatologists select appropriate therapies for the effect profiles to select the appropriate therapy for treatment of alopecia (Table). each patient. Minoxidilnot Minoxidil has been known to improve hair growth for more than 40 years. Oral minoxidil was first introduced Patterned hair loss is common and can negatively impact quality of for hypertension in the 1970s with a common adverse life. Patients often seek nonsurgical treatment options as a first-lineDo measure to avoid undue risks and expense associated with surgery. effect of hypertrichosis; the 2% solution was marketed for 4 This article discusses these noninvasive treatment options, with a AGA shortly thereafter in 1986. Minoxidil is a biologic focus on minoxidil, finasteride, dutasteride, spironolactone, low-level response modifier that is thought to promote hair growth laser therapy (LLLT), platelet-rich plasma (PRP), microneedling, and through vasodilation and stimulation of hair follicles into oral supplements.
    [Show full text]
  • Health Risks Associated with Long-Term Finasteride and Dutasteride Use: It’S Time to Sound the Alarm
    Review Article Health promotion, disease prevention, and lifestyle pISSN: 2287-4208 / eISSN: 2287-4690 World J Mens Health 2020 Jul 38(3): 323-337 https://doi.org/10.5534/wjmh.200012 Health Risks Associated with Long-Term Finasteride and Dutasteride Use: It’s Time to Sound the Alarm Abdulmaged M. Traish Department of Urology, Boston University School of Medicine, Boston, MA, USA 5α-dihydrotestosterone (5α-DHT) is the most potent natural androgen. 5α-DHT elicits a multitude of physiological actions, in a host of tissues, including prostate, seminal vesicles, hair follicles, skin, kidney, and lacrimal and meibomian glands. How- ever, the physiological role of 5α-DHT in human physiology, remains questionable and, at best, poorly appreciated. Recent emerging literature supports a role for 5α-DHT in the physiological function of liver, pancreatic β-cell function and survival, ocular function and prevention of dry eye disease and kidney physiological function. Thus, inhibition of 5α-reductases with finasteride or dutasteride to reduce 5α-DHT biosynthesis in the course of treatment of benign prostatic hyperplasia (BPH) or male pattern hair loss, known as androgenetic alopecia (AGA) my induces a novel form of tissue specific androgen deficien- cy and contributes to a host of pathophysiological conditions, that are yet to be fully recognized. Here, we advance the con- cept that blockade of 5α-reductases by finasteride or dutasteride in a mechanism-based, irreversible, inhabitation of 5α-DHT biosynthesis results in a novel state of androgen deficiency, independent of circulating testosterone levels. Finasteride and dutasteride are frequently prescribed for long-term treatment of lower urinary tract symptoms in men with BPH and in men with AGA.
    [Show full text]
  • Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals
    Journal of Clinical Medicine Review Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals Carlotta Cocchetti 1, Jiska Ristori 1, Alessia Romani 1, Mario Maggi 2 and Alessandra Daphne Fisher 1,* 1 Andrology, Women’s Endocrinology and Gender Incongruence Unit, Florence University Hospital, 50139 Florence, Italy; [email protected] (C.C); jiska.ristori@unifi.it (J.R.); [email protected] (A.R.) 2 Department of Experimental, Clinical and Biomedical Sciences, Careggi University Hospital, 50139 Florence, Italy; [email protected]fi.it * Correspondence: fi[email protected] Received: 16 April 2020; Accepted: 18 May 2020; Published: 26 May 2020 Abstract: Introduction: To date no standardized hormonal treatment protocols for non-binary transgender individuals have been described in the literature and there is a lack of data regarding their efficacy and safety. Objectives: To suggest possible treatment strategies for non-binary transgender individuals with non-standardized requests and to emphasize the importance of a personalized clinical approach. Methods: A narrative review of pertinent literature on gender-affirming hormonal treatment in transgender persons was performed using PubMed. Results: New hormonal treatment regimens outside those reported in current guidelines should be considered for non-binary transgender individuals, in order to improve psychological well-being and quality of life. In the present review we suggested the use of hormonal and non-hormonal compounds, which—based on their mechanism of action—could be used in these cases depending on clients’ requests. Conclusion: Requests for an individualized hormonal treatment in non-binary transgender individuals represent a future challenge for professionals managing transgender health care. For each case, clinicians should balance the benefits and risks of a personalized non-standardized treatment, actively involving the person in decisions regarding hormonal treatment.
    [Show full text]
  • Gender-Affirming Hormone Therapy
    GENDER-AFFIRMING HORMONE THERAPY Julie Thompson, PA-C Medical Director of Trans Health, Fenway Health March 2020 fenwayhealth.org GOALS AND OBJECTIVES 1. Review process of initiating hormone therapy through the informed consent model 2. Provide an overview of masculinizing and feminizing hormone therapy 3. Review realistic expectations and benefits of hormone therapy vs their associated risks 4. Discuss recommendations for monitoring fenwayhealth.org PROTOCOLS AND STANDARDS OF CARE fenwayhealth.org WPATH STANDARDS OF CARE, 2011 The criteria for hormone therapy are as follows: 1. Well-documented, persistent (at least 6mo) gender dysphoria 2. Capacity to make a fully informed decision and to consent for treatment 3. Age of majority in a given country 4. If significant medical or mental health concerns are present, they must be reasonably well controlled fenwayhealth.org INFORMED CONSENT MODEL ▪ Requires healthcare provider to ▪ Effectively communicate benefits, risks and alternatives of treatment to patient ▪ Assess that the patient is able to understand and consent to the treatment ▪ Informed consent model does not preclude mental health care! ▪ Recognizes that prescribing decision ultimately rests with clinical judgment of provider working together with the patient ▪ Recognizes patient autonomy and empowers self-agency ▪ Decreases barriers to medically necessary care fenwayhealth.org INITIAL VISITS ▪ Review history of gender experience and patient’s goals ▪ Document prior hormone use ▪ Assess appropriateness for gender affirming medical
    [Show full text]
  • Basics of Hormone Therapy for Transgender Patients Julie K
    Basics of Hormone Therapy for Transgender Patients Julie K. Prussack, MD Northern Michigan Family Medicine Update June 27, 2019 Disclosures None Disclaimer: No medications are currently FDA-approved for gender alteration or affirmation. Discussion of treatment is based on expert opinion. Objectives 1. Understand the difference between informed consent and referral letter models for initiating hormone therapy. 2. Access UCSF Guidelines for the Primary and Gender- Affirming Care of Transgender and Gender Nonbinary People. 3. Understand the medications, routes, and doses typically used for feminizing and masculinizing therapy. 4. Understand typical expectations and monitoring for patients on feminizing or masculinizing therapy. Hormone Therapy • Goal to suppress endogenous hormones by providing exogenous hormones • Affects secondary sex characteristics • Masculinizing: testosterone • Feminizing: estrogen, anti-androgen, ?progesterone • Patients may desire surgery of body contours and genitalia • Referral letter vs. informed consent models Stroumsa et al. Gender affirming treatment ant transition-related care. URL: https://www.youtube.com/watch?v=3ixr0YgB0As WPATH • Incorporated in 1979 as the Harry Benjamin International Gender Dysphoria Association, changed name to World Professional Association for Transgender Health in 2007 • 7th version of Standards of Care (SOC) published in 2012 • Mission to promote evidence based care, education, research, advocacy, public policy, and respect in transgender health. World Professional Association for Transgender Health, 2016. URL: www.wpath.org WPATH Criteria for Hormone Therapy 1. Persistent, well-documented gender dysphoria 2. Capacity to make a fully informed decision and to consent for treatment 3. Age of majority in a given country (if younger, follow SOC for Puberty-Suppressing Hormones) 4. If significant medical or mental health concerns are present, they must be reasonably well-controlled.
    [Show full text]
  • Risk of Depression After 5 Alpha Reductase Inhibitor Medication: Meta-Analysis
    Original Article Prostate and male voiding dysfunctions pISSN: 2287-4208 / eISSN: 2287-4690 World J Mens Health Published online May 23, 2019 https://doi.org/10.5534/wjmh.190046 Risk of Depression after 5 Alpha Reductase Inhibitor Medication: Meta-Analysis Jae Heon Kim1,2 , Sung Ryul Shim3,4 , Yash Khandwala1 , Francesco Del Giudice5 , Simon Sorensen6 , Benjamin I. Chung1 1Department of Urology, Stanford University Medical Center, Stanford, CA, USA, 2Department of Urology and 3Urological Biomedicine Research Institute, Soonchunhyang University Seoul Hospital, Soon Chun Hyang University College of Medicine, Seoul, 4Department of Preventive Medicine, Korea University College of Medicine, Seoul, Korea, 5Department of Urology, Sapienza University of Rome, Rome, Italy, 6Department of Urology, Aarhus University Hospital, Aarhus, Denmark Purpose: Although five-alpha reductase inhibitor (5-ARI) is one of standard treatment for benign prostatic hyperplasia (BPH) or alopecia, potential complications after 5-ARI have been issues recently. This study aimed to investigate the risk of depres- sion after taking 5-ARI and to quantify the risk using meta-analysis. Materials and Methods: A total of 209,940 patients including 207,798 in 5-ARI treatment groups and 110,118 in control groups from five studies were included for final analysis. Inclusion criteria for finial analysis incudes clinical outcomes re- garding depression risk in BPH or alopecia patients. Overall hazard ratio (HR) and odds ratio (OR) for depression were ana- lyzed. Moderator analysis and sensitivity analysis were performed to determine whether HR or OR could be affected by any variables, including number of patients, age, study type, and control type. Results: The pooled overall HRs for the 5-ARI medication was 1.23 (95% confidence interval [CI], 0.99–1.54) in a random effects model.
    [Show full text]
  • Endocrine Therapy for Transgender Youth
    Endocrine Therapy for Transgender Youth Daniel L. Metzger, MD www.transyouthla.com Normal puberty girls breast development starts at 10 (8–12) growth spurt peak at 11½ (9½–12½) first period at 12½ (10½–14½) boys testicular enlargement starts at 11 (9–13) growth spurt peak at 13½ (11½–15½) considerable variability The overarching treatment goal “The general goal of psychotherapeutic, endocrine, or surgical therapy for persons with gender identity disorders is lasting personal comfort with the gendered self in order to maximize overall psychological well-being and self-fulfillment.” WPATH Standards of Care, 6th version Why treat kids under age 18? studies show less post-operative function is related to the “ability to pass” physical outcomes much better if patient treated before breast development, beard growth, deepening of the voice prevent developmental problems related to discrepancy between body and mind patients are suffering! How are kids different? still growing still accruing bone-mineral content still going through the physical changes of puberty still going through the psychological and developmental changes of puberty their GID may not be as “solidified” they have to deal with the school system Our approach to treating youth different from treating adults more of an attempt to mirror natural puberty therefore, end results appear more gradually use available guidelines and published experience (Netherlands!) WPATH Standards of Care, 6th version Vancouver Coastal Health, Transgender Health Program Endocrine Society CPG: Endocrine
    [Show full text]
  • Pharmacologic Basis for the Enhanced Efficacy of Dutasteride Against Prostatic Cancers Yi Xu, Susan L
    Cancer Therapy: Preclinical Pharmacologic Basis for the Enhanced Efficacy of Dutasteride against Prostatic Cancers Yi Xu, Susan L. Dalrymple, Robyn E. Becker, Samuel R. Denmeade, andJohn T.Isaacs Abstract Purpose: Prostatic dihydrotestosterone (DHT) concentration is regulated by precursors from systemic circulation and prostatic enzymes of androgen metabolism, particularly 5a-reductases (i.e., SRD5A1 and SRD5A2). Therefore, the levels of expression SRD5A1 and SRD5A2 and the antiprostatic cancer growth response to finasteride, a selective SRD5A2 inhibitor, versus the dual SRD5A1and SRD5A2 inhibitor, dutasteride, were compared. Experimental Design: Real-time PCR and enzymatic assays were used to determine the levels of SRD5A1and SRD5A2 in normal versus malignantratand human prostatic tissues. Ratsbearing the Dunning R-3327H rat prostate cancer and nude mice bearing LNCaP or PC-3 human prostate cancer xenografts were used as model systems. Tissue levels of testosterone and DHT were determined using liquid chromatography-mass spectrometry. Results: Prostate cancer cells express undetectable to low levels of SRD5A2 but elevated levels of SRD5A1activity compared with nonmalignant prostatic tissue. Daily oral treatment of rats with the SRD5A2 selective inhibitor, finasteride, reduces prostate weight and DHTcontent but did not inhibit R-3327Hrat prostate cancer growth or DHTcontent in intact (i.e., noncastrated) male rats. In contrast, daily oral treatment with even a low1mg/kg/d dose of the dual SRD5A1and SRD5A2 inhibitor, dutasteride, reduces both normal prostate and H tumor DHTcontent and weight in intact rats while elevating tissue testosterone. Daily oral treatment with finasteride significantly (P < 0.05) inhibits growth of LNCaP human prostate cancer xenografts in intact male nude mice, but this inhibition is not as great as that by equimolar oral dosing with dutasteride.This anticancer efficacy is not equivalent, however, to that produced by castration.
    [Show full text]
  • An Analysis on Whether Or Not Baldness Can Be Reversed
    The Science Journal of the Lander College of Arts and Sciences Volume 10 Number 2 Spring 2017 - 2017 An Analysis on Whether or Not Baldness Can Be Reversed Spencer Waldman Touro College Follow this and additional works at: https://touroscholar.touro.edu/sjlcas Part of the Integumentary System Commons Recommended Citation Waldman, S. (2017). An Analysis on Whether or Not Baldness Can Be Reversed. The Science Journal of the Lander College of Arts and Sciences, 10(2). Retrieved from https://touroscholar.touro.edu/sjlcas/ vol10/iss2/11 This Article is brought to you for free and open access by the Lander College of Arts and Sciences at Touro Scholar. It has been accepted for inclusion in The Science Journal of the Lander College of Arts and Sciences by an authorized editor of Touro Scholar. For more information, please contact [email protected]. An Analysis on Whether or not Baldness can be Reversed Spencer Waldman Spencer Waldman will graduate with a BS in Biology in September 2017. Abstract Many men experiencing hair loss often wonder: is there a cure? Can I get my hair regrown? This thesis addresses these very issues, the anatomy of the pilosebaceous hair, the hair growth cycle, and the suggested causes of male male pattern hair loss are examined. Finally, the Various drugs that have been suggested to reduce hair loss and even cause hair regrowth are reviewed. After examining the various treatments, it can be concluded with reasonable certainty that hair loss can be halted and often reversed by using FDA approved drugs finasteride and minoxidil.
    [Show full text]
  • Hormonal Therapies for Hidradenitis Suppurativa: Review
    Volume 23 Number 10 | October 2017 Dermatology Online Journal || Review DOJ 23 (10): 1 Hormonal therapies for hidradenitis suppurativa: Review Ashley K Clark1 BS, Rebecca L Quinonez2 BS, Suzana Saric1 BA, Raja K Sivamani3,4 MD MS CAT Affiliations:1 School of Medicine, University of California, Davis, Sacramento, California, 2School of Medicine, Universidad Autonoma de Guadalajara - San Antonio, Texas, 3Department of Dermatology, University of California, Davis, Sacramento, California, 4Department of Biological Sciences, California State University-Sacramento, Sacramento, California Corresponding Author: Raja Sivamani MD, MS, CAT, Department of Dermatology, University of California, Davis, 3301 C Street, Suite 1400, Sacramento, CA 95816, Tel: 916-703-5145, Fax: 916-734-7183, Email: [email protected] Abstract of the surrounding tissue [2]. Abscess formation is commonly seen and it can extend deep into the Hidradenitis suppurativa is a recurrent inflammatory subcutaneous tissue, further promoting deep sinus skin condition characterized by abscesses and boils, tract formation. Hypertrophic scarring is a common predominantly in the groin, armpit, and buttocks sequela of the condition, primarily affecting those areas. HS is not a life-threatening condition, but with darker skin tones. severely impairs quality of life in those affected. Finding a successful treatment approach for HS has Clinically HS presents as painful papules and nodules, been challenging, in part because of the lack of a gold- eventually progressing to abscess formation and standard treatment method, limited research-based severe scarring. It may also be characterized by information, and the nature of clinical variation in the having a malodorous sterile discharge. The severity of disease. Treatment commonly consists of antibiotics, the disease is described by the Hurley stages.
    [Show full text]
  • Androgens in Women: Hormone-Modulating Therapies For
    Androgens in women Hormone-modulating therapies for skin disease Sarah Azarchi, BS,a Amanda Bienenfeld, BA,a Kristen Lo Sicco, MD,b ShariMarchbein,MD,b Jerry Shapiro, MD,b and Arielle R. Nagler, MDb New York, New York Learning objectives After completing this learning activity, participants should be able to list, categorize, and explain the mechanisms of action, safety considerations, and contraindications of these androgen-modulating therapies; identify the hormone-modulating therapies used to treat acne, hirsutism, and androgenetic alopecia; and describe the evidence to support the efficacy of these therapies in the treatment of acne, hirsutism, and androgenetic alopecia. Disclosures Editors The editors involved with this CME activity and all content validation/peer reviewers of the journal-based CME activity have reported no relevant financial relationships with commercial interest(s). Authors The authors involved with this journal-based CME activity have reported no relevant financial relationships with commercial interest(s). Dr Shapiro is a stockholder in Replicel Life Sciences and has been a consultant for Aclaris, Samumed, Incyte, Bioniz, keeps.com, Applied Biology, and Pfizer. Planners The planners involved with this journal-based CME activity have reported no relevant financial relationships with commercial interest(s). The editorial and education staff involved with this journal-based CME activity have reported no relevant financial relationships with commercial interest(s). Androgen-mediated cutaneous disorders (AMCDs) in women, including acne, hirsutism, and female pattern hair loss, can be treated with hormone-modulating therapies. In the second article in this Continuing Medical Education series, we discuss the hormone-modulating therapies available to dermatologists for the treatment of AMCDs, including combined oral contraceptives, spironolactone, finasteride, dutasteride, and flutamide.
    [Show full text]
  • Role of Dutasteride in Preclinical ETS Fusionpositive Prostate Cancer Models
    The Prostate 72:1542^1549 (2012) Role of Dutasteride in Pre-Clinical ETS Fusion-Positive Prostate Cancer Models Bushra Ateeq,1,2 Adaikkalam Vellaichamy,1,2 Scott A. Tomlins,1,2 Rui Wang,1,2 Qi Cao,1,2 Robert J. Lonigro,1,3 Kenneth J. Pienta,1,3,4 and Sooryanarayana Varambally1,2,3* 1Michigan Center forTranslational Pathology,University of Michigan Medical School, Ann Arbor, Michigan 2Department of Pathology,University of Michigan Medical School, Ann Arbor, Michigan 3Comprehensive Cancer Center,University of Michigan Medical School, Ann Arbor, Michigan 4Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan BACKGROUND. Androgens play a crucial role in prostate cancer, hence the androgenic pathway has become an important target of therapeutic intervention. Previously we discov- ered that gene fusions between the 50-untranslated region of androgen regulated gene TMPRSS2 and the ETS transcription factor family members were present in a majority of the prostate cancer cases. The resulting aberrant overexpression of ETS genes drives tumor progression. METHODS. Here, we evaluated the expression levels of 5a-reductase isoenzymes in pros- tate cancer cell lines and tissues. We tested the effect of dutasteride, a 5a-reductase inhibitor, in TMPRSS2–ERG fusion-positive VCaP cell proliferation and cell invasion. We also evaluat- ed the effect of dutasteride on the TMPRSS2–ERG fusion gene expression. Finally, we tested dutasteride alone or in combination with an anti-androgen in VCaP cell xenografts tumor model. RESULTS. Our data showed that 5a-reductase SRD5A1 and SRD5A3 isoenzymes that are responsible for the conversion of testosterone to DHT, are highly expressed in metastatic prostate cancer compared to benign and localized prostate cancer.
    [Show full text]